Brimonidine-timolol versus brinzolamide-timolol for treatment of elevated intraocular pressure after phacoemulsification surgery

Basit Öğe Kaydı
dc.contributor.authorBalsak, Selahattin
dc.contributor.authorKaydu, Ayhan
dc.contributor.authorErdem, Seyfettin
dc.contributor.authorAlakus, M. Fuat
dc.contributor.authorOzkurt, Zeynep Gursel
dc.date.accessioned2024-04-24T16:02:12Z
dc.date.available2024-04-24T16:02:12Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractTo compare the efficacy of the fixed combination of brimonidine-timolol (FCBT) and the fixed combination of brinzolamide-timolol (FCBZT) treatments for elevated intraocular pressure (IOP) after phacoemulsification cataract surgery. A randomised, prospective, double-blinded study was conducted on 277 eyes of 257 patients who underwent phacoemulsification cataract surgery. Patients were divided into three groups based on the medication administered after cataract surgery as follows: FCBT, FCBZT and a control group where no antiglaucoma medications were used. IOP was recorded at preoperative and postoperative hours 6 and 24 and days 3 and 5. No statistical differences were observed among the groups regarding age, sex and baseline IOP levels (p > 0.05). Mean IOP levels were significantly lower in the treatment groups than in the control group at postoperative hours 6 and 24 and days 3 and 5 (p < 0.001). Administration of one drop of FCBT or FCBZT demonstrated similar effects on preventing IOP spikes within 24 h of phacoemulsification cataract surgery. FCBZT more effectively lowered IOP than FCBT at days 3 and 5 (p < 0.05). We demonstrate that the postoperative administration of FCBT or FCBZT is effective in lowering IOP after phacoemulsification cataract surgery; FCBZT more effectively lowered IOP than FCBT at postoperative days 3 and 5.en_US
dc.identifier.doi10.1007/s10792-017-0626-z
dc.identifier.endpage1589en_US
dc.identifier.issn0165-5701
dc.identifier.issn1573-2630
dc.identifier.issue4en_US
dc.identifier.pmid28674856
dc.identifier.scopus2-s2.0-85021845679
dc.identifier.scopusqualityQ2
dc.identifier.startpage1583en_US
dc.identifier.urihttps://doi.org/10.1007/s10792-017-0626-z
dc.identifier.urihttps://hdl.handle.net/11468/14681
dc.identifier.volume38en_US
dc.identifier.wosWOS:000439166500027
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIntraocular Pressureen_US
dc.subjectPhacoemulsificationen_US
dc.subjectBrimonidineen_US
dc.subjectBrinzolamideen_US
dc.subjectTimololen_US
dc.titleBrimonidine-timolol versus brinzolamide-timolol for treatment of elevated intraocular pressure after phacoemulsification surgeryen_US
dc.titleBrimonidine-timolol versus brinzolamide-timolol for treatment of elevated intraocular pressure after phacoemulsification surgery
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu